Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976708 | 0.95 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2979833 | 0.92 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2976024 | 0.90 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2966662 | 0.89 | PDE4B (0.40) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2976079 | 0.89 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2977979 | 0.85 | PDE4B (0.39) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2970111 | 0.83 | PDE4B (0.39) | PDE4APDE4BPDE4CPDE4DBCHE | |
| SCHEMBL2966349 | 0.83 | PDE4B (0.48) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2973629 | 0.81 | PDE4D (0.43) | PDE4APDE4BPDE4CPDE4DACHE | |
| SCHEMBL2977973 | 0.81 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772258-B2 | Agent for treatment of allergic eye disease | NIKKEN CHEMICALS CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20080306163-A1 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE | NIKKEN CHEMICALS CO., LTD. | 2008-12-11 | — | — | US | disclosed |
| EP-0994100-B1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | NIKKEN CHEMICALS CO LTD (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20040220227-A1 | Remedies for allergic eye diseases | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1410795-A1 | REMEDIES FOR ALLERGIC EYE DISEASES | Nikken Chemicals Company, Limited (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-6235736-B1 | ANTIINFLAMMATORY AGENTS | NIKKEN CHEMICALS CO., LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0994100-A1 | 3-ANILINO-2-CYCLOALKENONE DERIVATES | Nikken Chemicals Company, Limited (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220227-A1 | Remedies for allergic eye diseases | HRH2, HRH1, HRH4 | PDE4A 1663/4885PDE4B 2290/4885PDE4C 2319/4885 |
| US-20080306163-A1 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE | HRH4, HRH3, HRH2 | PDE4A 2224/4885PDE4B 2422/4885PDE4C 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.